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ABSTRACT 
Objective: Reviews on the psychosocial aspects of genetic testing for hereditary diseases 
typically focus on outcomes for carriers and non-carriers of genetic mutations. However, the 
majority of unaffected individuals from high-risk families do not undergo predictive testing. 
The aim of this review was to examine studies on psychosocial distress in unaffected 
individuals who delay, decline or remain ineligible for predictive genetic testing. 
 
Method: Systematic searches of Medline, CINAHL, PsychINFO, PubMed and 
handsearching of related articles published between 1990 and 2012 identified 23 articles 
reporting 17 different studies that were reviewed and subjected to quality assessment. 
 
Results: Findings suggest definitions of delaying and declining are not always 
straightforward and few studies have investigated psychological distress among individuals 
who remain ineligible for testing. Findings related to distress in delayers and decliners have 
been mixed, but there is evidence to suggest cancer-related distress is lower in those who 
decline genetic counselling and testing, compared with testers, and that those who remain 
ineligible for testing experience more anxiety than tested individuals. Psychological, 
personality and family history vulnerability factors were identified for decliners and 
individuals who are ineligible for testing.  
 
Conclusions: The small number of studies and methodological limitations preclude definitive 
conclusions. Nevertheless, subgroups of those who remain untested appear to be at increased 
risk for psychological morbidity. As the majority of unaffected individuals do not undergo 
genetic testing, further research is needed to better understand the psychological impact of 
being denied the option of testing, declining and delaying testing.
Introduction 
Despite early concerns over the potential for adverse psychological responses to genetic 
testing for disease risk [1], no systematic negative long-term psychological outcomes have 
been demonstrated [2, 3]. This may be attributable to the success of genetic counselling in 
facilitating adaptation to receiving genetic results as well as the benefits of reducing 
uncertainty regarding risk and providing information to guide screening, prevention or 
treatment decisions [4, 5]. However, little is known about the impact of not receiving genetic 
test results in the presence of a family history of disease.  
 
Most unaffected individuals from families with a strong history of disease are ineligible for 
personal testing [6] as they are usually only tested after a mutation has been identified in an 
affected relative [7, 8]. For this reason, the majority of unaffected relatives are assumed to be 
at increased risk, but do not benefit from genetic counselling or the reduced uncertainty of 
knowing their actual risk. In addition, over a third of individuals who are eligible for testing 
choose not to be tested (decliners), or are undecided about testing or plan to be tested at a 
later date (delayers) [9-11]. 
 
The few studies of those who are ineligible for testing suggest anxiety may be higher in this 
group compared with identified mutation carriers and population controls [12, 13], and 
studies comparing those who decline to those who opt for testing have produced mixed 
results [14-17]; few, if any, studies focus on those individuals who delay genetic testing.  
 
In light of the growing list of diseases for which a family history has been identified as a risk 
indicator, a systematic review of the psychological factors associated with delaying, declining 
or remaining ineligible for testing is timely. The aim of this systematic review was to answer 
the following questions: 1) What are the distress profiles of decliners and delayers? 2) What 
are the psychological outcomes for individuals who decline, delay or remain ineligible for 
testing? 3) What are the vulnerability factors for individuals who decline, delay or remain 
ineligible for testing? 
 
Method 
Search strategy 
Searches were conducted in PsychINFO, Medline, CINAHL and PubMed between April 27, 
2012 and May 8, 2012 and the results were limited to articles relating to adult humans that 
were published in English in a peer-reviewed journal since January 1, 1990. Search terms 
were developed, and adapted for each database, from the concepts of genetic testing, 
hereditary cancer, psychosocial factors and uncertainty, as well as additional terms such as 
‘absence of demonstrated mutation’. 
 
Reference lists of eligible articles were examined to identify additional relevant studies. 
Reference lists of reviews identified through searches were screened, and articles citing 
included papers were identified through Web of Knowledge and assessed for eligibility. 
 
Selection of eligible articles 
Articles were eligible for inclusion in this review if they reported original research and 
included 1) participants at increased risk for disease based on family history, known genetic 
mutation or ethnic descent; 2) results for participants who were ineligible for testing (and 
had, therefore, not undergone the testing procedure), eligible but declined to learn results, 
and/or eligible but delayed testing; 3) at least ten participants in the group of interest [18]; 
and, 4) at least one measure of distress or explored coping with risk qualitatively. Articles 
were excluded if the study 1) assessed affected individuals only; 2) did not report results 
separately for affected and unaffected individuals (studies not reporting results separately but 
which controlled for personal cancer history or found no effect of affected status were 
included); 3) did not provide a clear description of the genetic testing statuses of the groups; 
4) were review articles; or, 5) assessed only intentions to test. This last exclusion criterion 
was based on evidence that intention to undergo genetic testing is not necessarily indicative 
of behaviour [19, 20]. 
 
Information Extraction and Quality assessment  
A data extraction sheet was used to record variables such as study participants, research 
question, study design, disease type, measures used, results and limitations relevant to the 
present review. The Qualsyst tool was used to document study quality, as it provides criteria 
for assessing a range of research designs [21]. All articles were independently assessed by 
LH and PB and discrepancies discussed until agreement was reached. 
 
The studies relevant to the three review questions have been summarised under subheadings 
in Tables 1-3 and ordered according to quality of evidence, year of publication and 
alphabetically. Quality of evidence was ranked to reflect previously defined cut-offs [22] 
representing high (>80), moderate (70-80), adequate (50-70) and low (<50) quality. 
 
Importantly, differences in disease characteristics and associated risk management and 
treatment options (see Appendix 1 for a summary) have the potential to influence testing 
decisions and psychological outcomes, and should be considered in reviewing the results. 
How these differences are likely to impact decisions and outcomes is beyond the scope of this 
paper and has been outlined elsewhere [23]. 
 
Results 
The search yielded 1898 articles potentially eligible for review. Screening of titles, abstracts 
and exclusion of duplicate publications resulted in 91 articles being retrieved for full text 
screening. Application of inclusion/exclusion criteria and resolution of discrepancies reduced 
the number of articles for review to 17. Six additional articles were identified through 
reviews, citing articles and reference lists, resulting in 23 articles representing 17 different 
studies available for the review. Articles related to the same dataset or sample but reporting 
different data have been noted but reported separately. Articles presenting data relevant to 
more than one question of interest have been listed in all appropriate tables. 
 
Definitional challenges 
The distinction between declining and delaying testing was commonly acknowledged, but the 
classification of delayers and the concept of declining varied, reflecting the complexity of 
genetic test decision-making. Individuals who initially declined and either went on to 
undergo testing or indicated future testing as a possibility were variably grouped with testers 
and decliners, but never investigated independently. Decliners were sometimes separated into 
subgroups according to the stage at which they declined (e.g. pre- or post-counselling) or 
whether their testing decision was consistent with their pre-counselling test intention, and in 
one study it was not completely clear whether ‘declining’ was test decline or study 
participation decline. The authors of the current review chose to retain group classifications 
made by the study authors, but these complexities should be considered in the interpretation 
of the findings. 
 
Research Question 1: Distress profiles of decliners and delayers 
Eleven high quality articles presenting prospective data on this topic were identified (see 
Table 1). These articles assessed psychological distress prior to a decision about genetic 
testing being made, i.e. explored psychological predictors of decisions about testing. The 
majority of studies related to individuals at risk for familial breast and ovarian cancer 
(FBOC) with one each on hereditary non-polyposis colorectal cancer [HNPCC; 16] and 
Huntington’s Disease [HD; 24]. Types of distress reported included depression, anxiety, 
cancer-related distress (most often represented by the intrusion subscale of the Impact of 
Event Scale [IES; 25]), general distress, subjective well-being and hopelessness. The stressor 
referred to in the IES varied; participants responded in relation to “cancer” [17], “threat of 
breast cancer” [26], or “having a family history of cancer” [27]. In two studies, the focus of 
the cancer-related distress measure was not reported [16, 28]. 
 
Depression and anxiety 
Of eight studies comparing depression of decliners to testers, six reported no difference, one 
reported higher depression and one lower depression. Overall, contradictory findings may be 
attributable to differences in disease groups and/or measures used.  
 
Based on the larger and more recent studies, decliners of FBOC testing report lower 
depression while decliners of HNPCC testing report higher depression compared with testers. 
Lerman et al [16] found that depression was associated with declining in those at risk for 
HNPCC, while all studies of individuals at risk of FBOC reported no difference or lower 
depression in decliners. For example, Reichelt et al [17] investigated unaffected women (n = 
301) separately and found those who went on to decline BRCA1/2 testing had significantly 
lower levels of HADS-defined depressive symptoms, compared to testers (M = 2.0, SD = 2.6 
vs M = 1.3, SD = 1.8, p < .05), although other potential confounders were uncontrolled. 
Lerman et al [27] found no difference between testers and decliners in depression, controlling 
for potential confounders. Five comparisons that found no difference for FBOC did not 
control for potential confounders including affected status [1, 27-30]. Notably, all studies 
using the Centre for Epidemiological Studies Depression Scale CES-D reported no difference 
or higher depression in decliners [1, 16, 27-30], while Reichelt et al [17] reported lower 
depression in decliners as assessed by the HADS.  
 
Only two studies prospectively compared anxiety between testers and decliners and these 
show no difference between the groups. In women at risk of FBOC there were no differences 
between testers and decliners in anxiety in 301 unaffected women [17] or 126 women (46% 
affected) [28], however analyses did not control for potential confounders. 
 
Cancer-related distress 
We identified six studies that prospectively compared cancer-related distress in decliners and 
testers, with four reporting a lack of differences between the groups and two finding lower 
distress in decliners. However, the findings suggest that those who decline counselling and 
testing report lower levels of distress than testers and those who undergo counselling and then 
decline. For example, Lerman et al [27] found decliners (n = 63) at risk of FBOC who did not 
attend pre-notification education were more likely to report lower cancer-related distress 
(IES-intrusion score 0-1) than testers (n = 86), controlling for potential confounders. 
Similarly, Thompson et al found FBOC women who declined both counselling and testing 
reported the lowest levels of intrusion (M = 5.5, SD = 2.2) compared with those who declined 
after counselling (M = 11.9, SD = 2.0, p < .05) and those who were tested (M = 9.5, SD = 1.5, 
n.s.), with ‘high’ levels in 18%, 73% and 58% of individuals in each group, respectively, (Χ2 
(1, n = 75) = 11.2, p = 0.004) [26]. In contrast, decliners in four studies with no difference 
between groups all received counselling or education [16, 17, 19, 28]. Null findings were 
restricted either by uncontrolled analyses [16, 17, 28] or a small decliner group (n = 12) and 
unvalidated cancer-related distress measure [19]. 
 
General distress, hopelessness and well-being 
Four studies found no differences between decliners and testers on general distress [17, 24, 
28, 31], hopelessness [17] or subjective well-being [24]. These analyses did not control for 
potential confounders, although findings of Reichelt et al [17] relate to unaffected women 
only. The general distress measure used in one study was a composite score derived from a 
number of measures, some of which correlated with each other at only r = .42 [31], bringing 
into question its validity. 
 
Research question 2: Psychological outcomes for individuals who decline, delay or 
remain ineligible for testing 
Psychological outcomes – decliners (cross-sectional studies) 
Six studies compared distress of testers and decliners in cross-sectional analyses, i.e. after a 
decision had been made regarding genetic testing, with three high, two moderate and one 
adequate quality (see Table 2a). Two studies related to FBOC, and one each to HNPCC, HD, 
Li-Fraumeni Syndrome (LFS) and familial melanoma (FM). Studies assessed anxiety, 
depression and cancer-related distress and, where the IES was used, the stressor was “having 
a family history of cancer” [27], “LFS” [4] or “familial melanoma” [32].  
 
Depression and anxiety 
There were no significant differences between testers and decliners in anxiety or depression, 
although the relevant studies suffered a number of methodological limitations. Using the 
HADS, Lodder et al and de Snoo et al found no differences between testers and decliners at 
risk of FBOC [33] or FM [32], yet both decliner groups were small (n < 20) and overall 
sample size was deemed inadequate. As a result, potential confounders were uncontrolled. In 
addition, de Snoo et al [32] did not report results of significance tests to support their finding. 
Decruyenaere et al [34] also found no difference between testers and decliners in anxiety in 
bivariate analyses that precluded controlling for identified demographic differences between 
groups. 
 
Cancer-related distress 
Five studies assessed cancer-related distress; two found lower levels of cancer-related distress 
in decliners, one found no difference and two found higher cancer-related distress in 
decliners. Taking study quality into consideration, the findings suggest decliners may 
experience less cancer-related distress than testers. Two large studies, of 302 individuals at 
risk of FBOC [35] and 258 individuals at risk of HNPCC [36], found lower levels of cancer-
related distress in decliners compared with testers. However, in one study, timing of 
assessment for testers was unclear [35] and may have impacted distress levels, while in the 
other, declining participation in the study, presented as an opportunity to obtain “free genetic 
counselling, and the option of free genetic testing through a research study”, was the outcome 
variable of ‘test decline’ [36]. Therefore, test decline may have been confounded with study 
decline. In addition, a single item measured cancer-related distress, and age and education 
were uncontrolled, despite evidence of differences between groups on these variables [36] 
and well established correlations between these variables and cancer-related distress [37-40]. 
In spite of these limitations, we prioritised these findings on the basis of adequate sample size 
and the seriousness of the limitations in the other studies. 
 
Psychological outcomes – decliners (longitudinal studies) 
Six articles examined psychological outcomes of decliners in longitudinal studies that 
controlled for baseline levels (Table 2b). Direct comparison is limited by variations in 
measurement and conceptualisations of distress, and findings are complicated by 
methodological aspects. None of the studies reported better psychological outcomes for 
decliners. One study examined individuals with family histories of HD [24, 41], another 
study surveyed women at risk of FBOC [28, 31], and the samples in two articles on men and 
women at risk of FBOC may have overlapped [1, 30]. Compared with various groups, three 
of these studies reported worse outcomes for decliners, two reported no difference in 
outcomes for decliners, and one study reported mixed findings according to the comparison 
group and type of distress [28]. 
 
There is evidence of worse outcomes for decliners of HD testing across a range of outcomes, 
while there is stronger evidence of higher distress in decliners only in relation to cancer-
related distress and only compared with non-carriers, in individuals at risk of FBOC. Among 
individuals at risk of FBOC, decliners and carriers reported more intrusive thoughts than 
those with uninformative negative and variant results three months after baseline [28], more 
intrusive thoughts than those with variant results six months after baseline [28] and smaller 
reductions in depression compared with non-carriers one month post-testing decision [30]. 
Despite the evidence of differences between groups, changes over time within groups of 
those at risk for FBOC were either unassessed [1, 30] or showed no effect of time [28], thus 
although decliners may not report the same benefits as non-carriers, it is unknown whether 
changes in depression for decliners reflected deteriorations in psychological functioning. 
Wiggins et al [24] compared individuals at risk of HD who either received results indicating 
an increased (n = 37) or decreased (n = 58) risk, or had ‘no change’ in risk due to declining (n 
= 23) or uninformative results (n = 17) (groups combined due to lack of significant 
demographic or psychological differences). The ‘no change’ group reported deteriorations in 
psychological functioning compared with baseline, compared with testers and across a range 
of outcomes.  
 
Smith et al [28] did not find significant differences in overall distress, state anxiety or 
depression between testers and decliners, but the two other studies that reported no effect of 
study group on distress suffered from various limitations. FBOC decliners and testers did not 
report significantly different courses of distress over a six month period [30], however the 
composite distress measure may have been of questionable validity (refer to research question 
1 results). No significant difference was found between the groups at risk for HD (increased-
risk, decreased-risk, no change in risk, decliners) in rates of ‘adverse events’ [41], however 
the objective assessment of occurrence of an adverse event was not supplemented by the 
participant’s self-report and the small number of participants who had reported an adverse 
event precluded multivariate analyses. 
 
Psychological outcomes - ineligible for testing 
Two high quality studies of psychological outcomes in individuals who were ineligible for 
testing were identified in the literature [12, 13, 42, 43] (Table 2c). Overall, women at risk for 
FBOC who were ineligible for testing tended to report higher anxiety than mutation carriers, 
although findings for depression and cancer-related distress were mixed. Psychosocial 
distress (represented by scores on the General Health Questionnaire-28), mental quality of 
life, hopelessness, anxiety, depression, cancer-related distress (intrusion and avoidance 
related to 'cancer risk’ and 'being at risk of developing breast cancer') were investigated.  
 
In a series of cross-sectional comparisons, Geirdal et al compared women at risk for FBOC (n 
= 176) and HNPCC (n = 63) who were ineligible for testing to each other, BRCA1 mutation 
carriers (n = 68) and population controls [12, 42, 43]. Compared with mutation carriers, there 
were no significant differences in anxiety, depression, hopelessness, psychosocial distress, 
intrusion or avoidance for ineligible HNPCC women, however ineligible FBOC women 
reported higher levels of depression, psychosocial distress and mean anxiety, and no 
significant differences in prevalence of anxiety disorder, intrusion, avoidance and 
hopelessness [12, 42]. The combined FBOC/HNPCC group reported less depression, more 
anxiety, and comparable mental quality of life compared with population controls (Geirdal, et 
al., 2006; Geirdal, et al., 2005). 
 
In a prospective study, Meiser et al [13] compared 90 women at risk of FBOC who 
underwent testing to 53 women who were ineligible for testing on anxiety, depression and 
cancer anxiety. Testers reported significant reductions in anxiety over time, controlling for 
potential confounders. Interestingly, there was an increase in state anxiety for women who 
were ineligible for testing from baseline (M = 33.6, SD = 10.7) to 12 months (M = 39.0, SD = 
12.2). Although not reported, we estimated an effect size of 0.5, a moderate effect, using the 
baseline standard deviation [44] [(39-33.6)/10.7], and used the group size to calculate t = 
3.39, p < 0.05, demonstrating a significant increase in anxiety from baseline to 12 months for 
women who were ineligible for testing. Carriers tended to report higher cancer-related 
distress compared with the women who were ineligible for testing, however this may be due 
to differences in levels of familial cancer related events between participants with and 
without a known familial mutation. Depression levels did not differ between groups. 
 
Note that Geirdal et al’s ineligible women had undergone genetic counselling three months 
prior to participation, at which time they had been advised a mutation was assumed to be 
responsible for the family cancer history despite no mutation being identified [12]. In 
contrast, no risk information was available for ineligible women in the Meiser et al study 
[13]. 
 
Research question 3: Vulnerability factors for individuals who decline, delay or remain 
ineligible for testing 
Four high quality articles identified factors increasing an individual’s vulnerability to distress 
(Table 3). One prospective study assessed affected and unaffected American men and women 
at risk of FBOC who declined testing [1]. Geirdal et al reported cross-sectional data on 
unaffected women who were ineligible for testing from Norway in three articles with 
considerable sample overlap [42, 43, 45]. Two articles report cross-sectional data from a 
study of women at risk of FBOC and HNPCC. Due to a lack of significant differences 
between the risk groups, their data are combined in the analyses. One article reports the 
relationships between variables within the risk group [45], the other investigates relationships 
between variables and compares the risk group with population controls [43]. The third 
Norwegian article reports data from the FBOC group in the aforementioned study and 
compares them with a group of BRCA1 mutation carriers [42]. 
 
The four articles report that cancer-related distress (IES stressor “having cancer in the 
family” [1]), demographics, family history, personality and coping style are vulnerabilities 
for poorer mental quality of life, anxiety and depression. Evidence from these studies 
suggests that: 
1. decliners who report high levels of cancer-related distress at baseline are more likely 
to develop clinically significant depressive symptoms than carriers and non-carriers 
[1]; 
2. among women at risk of FBOC who remain ineligible for testing, focus on emotions, 
venting of emotions and avoidance through behavioural disengagement are associated 
with increased prevalence of anxiety disorder [42]; 
3. among women at risk of FBOC and HNPCC who remain ineligible for testing: 
• persistence, the tendency to avoid harm, less self-directedness and less 
optimism are associated with higher levels of mental distress (combined 
anxiety and depression), and these traits demonstrate stronger associations 
with mental distress than demographic and cancer-related variables [45]; 
• not having a partner is associated with increased risk of poorer mental quality 
of life [43]; 
• higher levels of intrusion and avoidance are associated with poorer mental 
quality of life [43]. 
Discussion 
We reviewed studies investigating distress in unaffected individuals at increased familial risk 
for disease who had not undergone genetic testing. These individuals comprise the majority 
of unaffected, at-risk family members and have been under-researched thus far. The majority 
of the identified studies have been conducted with members of hereditary cancer registries 
and involve individuals at risk for FBOC. At this time, research investigating distress in 
individuals who decline, delay or remain ineligible for Huntington’s disease genetic testing is 
sparse and insufficient to allow a meaningful comparison with individuals at risk of 
hereditary cancer. The included studies, from seven different countries, are a mixture of 
longitudinal and cross-sectional studies with most of the relevant findings pertaining to 
decliners. This review identified few studies of individuals who were ineligible for testing 
and no studies reporting results for delayers as a group distinct from decliners. Past research 
has, justifiably, focused on the psychological well-being of individuals who undergo genetic 
testing, however this review points to a need to monitor distress levels in those who remain 
untested as well. 
 
Those who declined to be involved in the genetic testing process altogether tended to report 
less cancer-related distress than testers. However, decliners have reported little confidence in 
their ability to cope with an unfavourable test result compared with testers [32, 36], implying 
the decision to decline involvement is made in the interest of avoiding distress. This indicates 
that test takers are likely to be self-selected [46], highlighting the importance of preserving 
autonomy in genetic testing decisions [41] and supporting the idea that anticipatory distress 
may lead to avoidance, while current distress may motivate a desire for genetic testing as a 
means to manage distress [26]. Some at-risk individuals perceive little value in finding out 
their result, particularly if they have no intentions of changing their risk management 
strategies regardless of the outcome [47], therefore the anticipated distress of a positive result 
justifies declining testing. Longer term psychological benefits of declining mutation testing 
remain unclear and further research is needed to elucidate the nature of these.  
 
What is clear from this review is that not all decliners are the same. Some are passive 
decliners who are aware of the opportunity to undergo testing and choose not to approach 
genetic services. Such individuals often also decline to be involved in research studies [30], 
or are never invited to participate in research as a result of their non-attendance at familial 
cancer clinics. Consequently, the true denominator of potential testers is likely unknown. 
Further, significantly more test decliners, compared with testers, withdraw from studies prior 
to completion [1]. Both issues may account for the small numbers of decliners, and the 
associated lack of statistical power, in many of the reviewed studies. Thus the findings from 
this review may not be generalizable to the population of individuals who choose not to 
undergo genetic testing.  
 
Another group of decliners seek risk information from genetic services but do not seek 
genetic testing. Others commence the testing process by giving a blood sample but do not 
return for the testing results. Some of these decliners undergo testing at a later date or at least 
indicate interest in later testing [19, 34, 35]. The findings of this review support the assertion 
that one group consciously decides to remain untested while another group engages in an 
avoidant coping strategy and may not cope as well as the former group [34], confirming a 
need for ‘delayers' to be considered separately. 
 
Individuals with increased familial risk for disease who remain ineligible for genetic testing 
are an understudied group. The available evidence to date indicates that women who remain 
ineligible for testing for FBOC have higher levels of general anxiety than both women who 
have undergone testing and the general population. Whether general anxiety is directly 
related to genetic testing is unclear. Baum et al.’s model of stress and genetic testing [48] 
suggests that reducing uncertainty through genetic testing may be psychologically beneficial, 
thus the ongoing uncertainty of remaining ineligible for testing may be experienced as 
distressing. This model also proposes that being identified as a carrier may exacerbate 
distress related to the disease itself, and this might explain why carriers reported more cancer-
related distress than women who were ineligible for testing. However, we know that stress 
related to non-familial cancer events is associated with increased anxiety in women at 
increased risk of FBOC and that stress specifically related to familial cancer events is 
associated with increased cancer-related distress rather than general anxiety [39]. Therefore, 
since familial cancer-related events are likely to be more common in families with identified 
mutations, any actual difference between the groups on this variable may have confounded 
results. Future studies comparing women with and without identified familial mutations 
should consider assessing this variable as a potential covariate.  
 
The findings of this review indicate a need for support to be available for untested 
individuals. A number of demographic, psychosocial and family history factors have been 
associated with an increased risk of distress in untested individuals, consistent with research 
on those at risk for FBOC [39, 49] and HD [50]. Formal risk assessment and/or genetic 
counselling may not be sought in the absence of an identified mutation, but many of the high-
risk individuals in the studies reviewed here were members of hereditary cancer registries and 
this membership may present opportunities to offer support. For example, additional support 
could be offered to those who decline testing following education or counselling, and to 
decliners who present with elevated cancer-related distress. Individuals who remain ineligible 
for testing may find the shared understanding of support groups helpful in relieving general 
anxiety. However, to date there is insufficient evidence to justify the cost-effectiveness of 
providing additional support. Further research is needed to establish what, if any, resources 
should be considered for use in these populations and how best to identify individuals whose 
distress levels warrant referral for additional support. 
 
One limitation of this review was that our criteria excluded a number of potentially eligible 
qualitative studies of individuals who were ineligible for testing that did not report separate 
results for affected and unaffected individuals [e.g. 51, 52, 53]. Due to the nature of 
qualitative inquiry, separate reporting of results for affected and unaffected individuals may 
not be appropriate. However, we deemed this exclusion criterion necessary since motivations 
for testing and distress responses to testing outcomes differ between affected and unaffected 
individuals [54]. Although this criterion was applied in the search process, we still reported 
results of bivariate analyses where affected status was uncontrolled. We did so because if test 
status was unrelated to distress in bivariate analyses these distress variables were often not 
included in multivariate analyses, particularly when these variables were not central to the 
study’s aims. Future studies focused on the needs and functioning of unaffected individuals 
will expand our knowledge in this area. Most of the articles on women who were ineligible 
for testing included in this review used the same sample, limiting generalisability of these 
findings. Further, international variations in the procedures and rules governing risk 
assessment, genetic counselling and genetic testing complicate the generalisability of any 
study in this field [55]. 
 
The majority of unaffected high-risk individuals remain untested. The absence of research on 
delayers, mixed findings on decliners and our limited understanding of how individuals cope 
with being ineligible for testing indicate an urgent need to assess psychosocial functioning in 
these groups. Future studies could explore the experience of being ineligible for testing, how 
risk is understood within this context, what type of information, if any, is sought and the 
relationship between being ineligible for testing and psychological distress. Once these 
aspects are better understood, psychological functioning and risk factors for distress in 
individuals who are ineligible for testing should be assessed in settings that accurately reflect 
their experiences to improve generalisability of the findings. 
 
Psychosocial support is routine for those seeking genetic testing. The results of this review 
indicate that individuals who do not undergo testing may also benefit from such support. 
Since one-on-one counselling resources are limited, this highlights the need for further 
research to identify those at highest risk for poorer psychological outcomes so that 
interventions can be targeted to individuals with the greatest need. 
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Table 1. Distress profiles of decliners and delayers 
    Authors, year, 
country 
Design and Method Sample 
+ve = carrier 
-ve = non-carrier 
Measures 
(-) indicates unvalidated 
measures 
Control 
variables 
Relevant Findings Limitations 
High quality             
Dougall, Smith, 
Somers et al., 2009, 
USA# 
Design: Prospective 
Method: Baseline 
(post-counselling, pre-
test decision) 
questionnaires, post-
baseline test decision 
n = 100 testers, 26 decliners 
FBOC women who were 
considering testing, recruited 
through a genetics program 
at a tertiary hospital, 46% 
affected 
Distress (composite score 
calculated from GSI:SCL-
90, IES, PSS, STAI, CES-
D) 
 
 
 
 No difference between testers and decliners in 
distress at baseline. 
Baseline comparison did 
not control for potential 
covariates 
Composite score of 
questionable validity - 
calculated from variables 
correlated with each other 
as low as 0.42. 
Smith, Dougall, 
Posluszny et al., 
2008, USA# 
Design: Prospective 
Method: Baseline 
(post-counselling, pre-
test decision) 
questionnaires, post-
baseline test decision 
n = 100 testers, 26 decliners 
FBOC women who were 
considering testing, recruited 
through a genetics program 
at a tertiary hospital, 46% 
affected 
Overall distress 
(GSI:SCL-90) 
Cancer-related distress 
(IES) 
State anxiety (STAI) 
Depressive symptoms 
(CES-D) 
 No difference between testers and decliners in 
depression, anxiety or general distress at 
baseline. 
Baseline comparison did 
not control for potential 
covariates 
 
Kelly, Leventhal, 
Andrykowski et al., 
2004, USA 
Design: Prospective 
Method: Baseline (pre-
counselling) 
questionnaire, post- 
counselling test 
decision 
n = 94 testers (20+ve, 6-ve, 
68 uninformative), 12 
decliners  
FBOC Ashkenazi Jewish 
women who met pre-defined 
mutation-risk criteria, self- or 
physician-recruited, 50% 
affected 
(-)  Cancer-related 
distress (9 items adapted 
from POMS) 
Pre-counselling test 
intention (-10; 'absolutely 
will not' to 10; 'absolutely 
will') 
Self-reported provision of 
blood sample (yes/no) 
Receipt of test result 
(did/did not) 
Age, 
education, 
income, 
affected 
status 
No differences in cancer-related distress 
between decliners and testers who had no 
change in intentions to test.  
Pre-counselling trend for decliners to report 
higher cancer-related distress than testers 
who changed intentions to test (p = .07). Post-
counselling trend for decliners to report higher 
cancer-related distress than testers who 
changed intentions to test (p = .07).  
Unvalidated distress 
measure 
Decliner group small n 
Reichelt, Heimdal, 
Moller & Dahl, 
2004, Norway 
Design: Prospective  
Method: Baseline (pre-
counselling) 
questionnaire, post-
counselling test 
decision  
n = 287 testers, 58 decliners 
(not tested within 6mths of 
counselling) 
FBOC women from 
mutation-positive families 
registered with a hospital 
medical genetics unit, 15% 
affected 
 
Anxiety and depression 
(HADS) 
General distress (GHQ-
28) 
Hopelessness (BHS) 
Cancer-related distress - 
avoidance and intrusive 
thoughts related to 
'cancer' (IES) 
 In unaffected women (n = 301), testers (n = 
244) had a higher mean depression score than 
decliners (n = 57). No differences in anxiety, 
cancer-related distress, general distress or 
hopelessness. 
Baseline comparison, 
although carried out 
separately for unaffected, 
did not control for other 
potential covariates 
Thompson, 
Valdimarsdottir, 
Duteau-Buck et al., 
2002, USA 
Design: Prospective 
Method: Baseline (pre-
counselling) 
questionnaire, post-
counselling test 
decision 
n = 40 testers (GC+GT+), 17 
counselling decliners (GC-), 
19 counsellees who declined 
testing (GC+GT-) 
Unaffected African-American 
FBOC women enrolled in 
longitudinal study through a 
clinical genetics service 
Cancer-related distress - 
intrusive thoughts related 
to 'the threat of breast 
cancer' (IES)  
Unique 
contribution of 
variables 
assessed by 
logistic 
regression 
Intrusive thoughts were independently 
associated with counselling/testing status. The 
GC- group reported less intrusive thoughts 
compared with GC+GT-. The GC+GT+ group 
did not report significantly different intrusive 
thoughts to either of the other groups. 
  
 
 
 
 
 
    
Table 1. (Continued) 
Authors, year, 
country 
Design and Method Sample 
+ve = carrier 
-ve = non-carrier 
Measures 
(-) indicates unvalidated 
measures 
Control 
variables 
Relevant Findings Limitations 
Biesecker, Ishibe, 
Hadley et al., 2000, 
USA 
Design: Prospective  
Method: Baseline (pre-
counselling) 
questionnaire, post-
counselling test 
decision 
n = 135 testers (includes 
"several" delayers), 37 
decliners 
FBOC men and women 
enrolled in a familial cancer 
study at the National Cancer 
Institute, 8% affected 
Depression (CES-D)  No difference between testers and decliners in 
depression at baseline. 
Baseline comparison did 
not control for potential 
covariates 
Delayers (exact number 
unreported) not separated 
from testers 
 
Lerman, Hughes, 
Trock et al., 1999, 
USA 
Design: Prospective 
cohort study 
Method: Baseline (pre-
education) phone 
interview, post-
counselling decision to 
receive results 
n = 84 testers (35+ve, 49-
ve), 55 decliners 
HNPCC men and women 
from 4 extended HNPCC 
mutation-positive families, 
19% affected 
Depression (CES-D) 
Cancer-related distress - 
intrusive thoughts (IES) 
Intra-family 
clustering, 
education, 
blood 
provision, 
marital 
No difference between testers and decliners in 
cancer-related distress. 
Clinically significant levels of depressive 
symptoms (18% of sample) were associated 
with four-fold reduced uptake in women and 
two-fold reduced uptake in men. 
Cancer-related distress 
comparison did not control 
for potential covariates 
Lerman, Hughes, 
Lemon et al., 1998, 
USA^ 
Design: Prospective 
cohort study 
Method: Phone 
interview at baseline 
(pre-education), post-
education test decision 
n = 206 testers (97+ve, 109-
ve), 121 decliners 
Affected and unaffected 
FBOC men and women from 
mutation-positive families 
registered at a hereditary 
cancer unit 
Depression (CES-D)  No difference between testers and decliners in 
depression at baseline. 
Baseline comparison did 
not control for potential 
covariates 
% affected not reported 
Lerman, Schwartz, 
Lin, et al., 1997, 
USA*^ 
Design: Prospective 
Method: Baseline 
(post-notification of 
availability of testing/ 
pre-counselling) 
telephone interview, 
post-counselling 
decision to receive 
results 
n = 86 testers, 63 decliners 
FBOC men and women from 
11 families registered at a 
hereditary cancer unit, 17% 
affected 
Outcome: Testing 
decision 
Predictors: Cancer-related 
distress - intrusive 
thoughts about 'having a 
family history of cancer' 
(IES) and general distress 
(CES-D)  
Gender, 
objective risk 
(where 
affected = 
100%), age, 
education, 
intra-family 
clustering 
Those with lower IES scores (0-1) were more 
likely to decline than those with moderate (2-9) 
or higher (10+) scores.  
No difference between testers and decliners in 
depression (general distress) at baseline. 
 
Lerman, Narod, 
Schulman et al., 
1996, USA*^ 
Design: Prospective 
cohort study 
Method: Baseline 
phone interview (pre-
education and pre-test 
decision) 
 
n = 115 testers (53+ve, 62-
ve), 77 decliners 
FBOC men and women from 
13 mutation-positive families 
registered at a hereditary 
cancer unit, 20% affected 
Depression (CES-D)  No difference between testers and decliners in 
depression at baseline. 
 Baseline comparison did 
not control for potential 
covariates 
 
Wiggins, Whyte, 
Huggins et al., 
1992, Canada 
Design: Prospective 
Method: 
Questionnaires at 
baseline (initial 
counselling), post-
counselling test 
decision. 
n = 95 testers (37 increased 
risk, 58 decreased risk), 40 
'no change' (23 decliners, 17 
uninformative result) 
Unaffected men and women 
at risk of HD participating in 
national genetic testing 
program 
Psychological distress 
(GSI:SCL-90) 
Depression (BDI) 
Well-being (GWBS) 
 No differences between testers and decliners 
at baseline in psychological distress, 
depression or well-being. 
 
 
 
 
# * indicates studies with overlapping samples 
^ indicates studies which may have some overlap in samples 
FBOC, Familial Breast/Ovarian Cancer; POMS, Profile of Mood States; HADS, Hospital Anxiety and Depression Scale; GHQ-28, General Health Questionnaire; BHS, Beck Hopelessness Scale; IES, Impact of 
Event Scale; GC, Genetic Counselling; GT, Genetic Testing; CES-D, Center for Epidemiological Studies Depression scale; HNPCC, Hereditary Non-Polyposis Colorectal Cancer; HD, Huntington’s Disease; 
STAI, Spielberger State Trait Anxiety Inventory 
 
 
    
Table 2a. Outcomes for decliners (cross-sectional) 
Authors, year, 
country 
Design and Method Sample 
+ve = carrier 
-ve = non-carrier 
Measures 
(-) indicates unvalidated 
measures 
Control 
variables 
Relevant Findings Limitations 
High quality             
Foster, Evans, 
Eeles et al., 2004, 
UK 
Design: Cross-
sectional 
Method: Baseline (at 
counselling, pre-test 
decision) questionnaire, 
compared to decliners 
CWS scores from 
separate questionnaire 
completed 12mths 
post-baseline 
n = 275 testers, 27 decliners 
(including 5 delayers [tested 
post-participation]) 
Unaffected FBOC men and 
women from mutation-
positive families who 
attended genetic centres for 
genetic counselling 
Cancer worry (CWS) Age No demographic differences between 
decliners and delayers and testers.  
After controlling for age, decliners report less 
cancer worry than testers. 
Delayers small n. 
Delayers not separated 
from decliners. 
Timing of assessments may 
have impacted distress 
levels. 
Codori, Peteresen, 
Miglioretti et al., 
1999, USA 
Design: Cross-
sectional 
Method: Self-report 
questionnaire for 
testers, phone interview 
for decliners 
n = 77 testers, 181 decliners  
Unaffected men and women 
at risk of HNPCC 
participating in a colorectal 
cancer registry 
Dependent variable: 
Testing decision  
Independent variable: 
frequency of cancer 
thoughts in past month (1 
item, 4-point Likert scale) 
Distance from 
hospital, intra-
family 
clustering 
More frequent cancer thoughts were 
significantly associated with study participation 
and, consequently, test uptake.  
Test decline confounded 
with study decline. 
Age and education not 
controlled, despite 
differences. 
Single item to measure 
cancer-related distress 
Decruyenaere, 
Evers-Kiebooms, 
Boogaerts et al., 
1997, Belgium 
Design: Cross-
sectional 
Method: Self-report 
questionnaire 
n = 63 testers, 14 decliners 
(applied for testing), 36 
siblings (never applied for 
testing) 
Unaffected men and women 
at risk of HD who applied for 
testing at a genetics centre 
(and their siblings) 
Anxiety (STAI)   Untested groups were pooled. No difference in 
anxiety between testers and decliners. 
Bivariate statistical 
analyses precluded 
controlling for parity, which 
differed between tested and 
untested. 
Moderate quality             
Lammens, 
Aaronson, Wagner 
et al., 2010, The 
Netherlands 
Design: Cross-
sectional 
Method: Self-report 
questionnaire 
n = 52 testers (27+ve, 25-
ve), 18 decliners/ delayers (4 
had future testing intentions, 
8 unsure about testing, 6 no 
intention to be tested) 
Men and women from 11 
LFS mutation-positive 
families, 14% affected 
Cancer-related distress - 
intrusive thoughts related 
to 'LFS' (IES) 
Cancer worry (CWS)  
Age, gender No differences in the number of decliners 
(17%), carriers (22%) and non-carriers (29%) 
reporting clinically significant levels of intrusive 
thoughts.  
No differences between groups in cancer 
worry. 
Insufficient n. 
Unable to control for familial 
clustering. 
Lodder, Frets, 
Trijsburg et al., 
2003, The 
Netherlands 
Design: Cross-
sectional 
Method: Self-report 
questionnaire and/or 
telephone interview 
(decliners aware of 
possibility of testing 
>1yr earlier and did not 
apply for testing, testers 
assessed between 
blood sampling and 
result notification) 
n = 85 testers, 13 decliners 
Decliners: women at risk of 
Testers: women who 
underwent testing between 
December 1995 and April 
1998  
FBOC participating in 
surveillance program at a 
cancer institute.  
 
Anxiety and depression 
(HADS) 
(-) Cancer-related distress 
(9 items from IES) 
  No difference in cases of borderline-high 
anxiety and/or depression between decliners 
and testers.  
No difference in anxiety or depression 
between decliners and testers.  
4/13 of the decliners reported at least 1 item in 
the cancer-related distress scale applied to 
them ‘often’. The authors stated that "the 
others reported lower cancer-related distress 
levels", however no significance test was 
reported. 
Affected status unreported 
but assumed to be 
unaffected. 
Timing of testers' 
assessment may have 
affected distress. 
Insufficient n. 
Evidence of between group 
demographic differences 
but  small sample precluded 
multivariate analyses. 
Significance of between 
group differences in cancer-
related distress not 
reported. 
 
 
Table 2a. (Continued) 
    Adequate quality          
de Snoo, Riedijk, 
van Mil et al., 2008, 
The Netherlands 
Design: Cross-
sectional 
Method: Self-report 
questionnaire 0-6wks 
post-counselling/pre-
testing 
n = 75 testers, 19 decliners 
Men and women at risk of 
FM from 13 mutation-
positive families associated 
with a tertiary medical centre 
skin screening clinic (Note: 
The melanoma mutation is 
also associated with a 17% 
pancreatic cancer risk) 
Anxiety and depression 
(HADS) 
Cancer-related distress 
(IES) 
(-) DNA test expectancies 
(12 items, 5-point Likert 
scale) 
(-) Impact of pancreatic 
cancer information (3 
items, 5-point Likert scale) 
Gender,  
education 
"Fears induced by the test result" and 
"worries" about melanoma and pancreatic 
cancer (from DNA test expectancies) were 
significantly associated with test decline. 
Both testers and decliners had low scores on 
the HADS, but no significance tests were 
reported. Did not report differences between 
testers and decliners for Impact of pancreatic 
cancer information, despite saying this was 
assessed. 
Unclear whether 
psychological questionnaire 
before or at time of decline. 
Used unvalidated 
measures. 
Insufficient n and poor 
response rate (51%) 
"Given the relatively small 
sample size, only gender 
and educational level were 
entered as possible 
covariates" (p.793). 
Significance of between 
group differences in HADS 
scores not reported. 
* indicates studies with overlapping samples 
FBOC, Familial Breast/Ovarian Cancer; CWS, Cancer Worry Scale; HNPCC, Hereditary Non-Polyposis Colorectal Cancer; HD, Huntington’s Disease; STAI, Spielberger State Trait Anxiety Inventory; LFS, Li-
Fraumeni Syndrome; IES, Impact of Event Scale; HADS, Hospital Anxiety and Depression Scale; FM, Familial Melanoma 
 
Table 2b. Outcomes for decliners (longitudinal) 
Authors, year, 
country 
Design and Method Sample 
+ve = carrier 
-ve = non-carrier 
Measures 
(-) indicates unvalidated 
measures 
Control 
variables 
Relevant Findings Limitations 
High quality             
Dougall, Smith, 
Somers et al., 
2009, USA* 
Design: Prospective 
Method: Questionnaires 
at baseline (post-
counselling, pre-test 
decision), 1 week post-
result or 3-4mths post-
baseline for decliners 
(T2), 3mths post-T2, 
6mths post-T2 
n = 100 testers (positive, 
negative [uninformative], 
variant), 26 decliners 
FBOC women who were 
considering testing, recruited 
through a genetics program at 
a tertiary hospital, 46% 
affected 
Distress (composite score 
calculated from GSI:SCL-
90, IES, PSS, STAI, CES-
D) 
 
 
 
Age, 
income, 
use of 
psychiatric 
medication 
No difference between testers and decliners in 
distress at any time point. 
Composite distress score of 
questionable validity - 
calculated from variables 
correlated with each other 
as low as 0.42. 
Tested subgroup ns 
unreported 
Smith, Dougall, 
Posluszny et al., 
2008, USA* 
Design: Prospective 
Method: Questionnaires 
at baseline (post-
counselling, pre-test 
decision), 1 week post-
result or 3-4mths post-
baseline for decliners 
(T2), 3mths post-T2, 
6mths post-T2 
n = 100 testers (positive, 
negative [uninformative], 
variant), 26 decliners 
FBOC women who were 
considering testing, recruited 
through a genetics program at 
a tertiary hospital, 46% 
affected 
Overall distress 
(GSI:SCL-90) 
Cancer-related distress 
(IES) 
State anxiety (STAI) 
Depressive symptoms 
(CES-D) 
Age, 
income, 
education, 
use of 
psychiatric 
medication 
No difference between groups in cancer-
related distress at baseline or 1week post-
result, but 3mths post-test those with 
uninformative/negative or variant results 
reported less intrusion than decliners and 
carriers. At 6mths decliners reported 
significantly more cancer-related distress than 
those with variant results. 
Tested subgroup ns 
unreported 
Lerman, Hughes, 
Lemon et al., 
1998, USA^ 
Design: Prospective 
cohort study 
Method: Phone 
interview at baseline 
(pre-education), 1mth & 
6mth follow-up  
n = 206 testers (97+ve, 109-
ve), 121 decliners 
FBOC men and women from 
mutation-positive families 
registered at a hereditary 
cancer unit 
Cancer-related distress - 
intrusive thoughts about 
'having cancer in the 
family' (IES) 
Depression (CES-D) 
Baseline 
depression, 
gender, 
affected 
status, 
marital 
status 
No difference between groups in depression at 
baseline. Significant difference in prevalence 
of depression at 1mth - 8% non-carriers, 14% 
carriers and 19% decliners. Multivariate 
analyses revealed that higher rates of 
depression at follow-up were only seen for 
decliners with elevated baseline cancer-
related distress (see Table 3).  
 
% affected not reported 
 
  
Table 2b. (Continued) 
Lerman, Narod, 
Schulman et al., 
1996, USA^ 
Design: Prospective 
cohort study 
Method: Baseline (1-
2mths pre-education) 
phone interview, 1mth 
follow-up phone 
interview (1mth post-
testing decision/result 
notification)  
n = 115 testers (53+ve, 62-ve), 
77 decliners 
FBOC men and women from 
13 mutation-positive families 
registered at a hereditary 
cancer unit, 19% affected 
Depression (CES-D) Intra-family 
clustering, 
affected 
status, 
baseline 
levels of 
outcome 
variables 
For unaffected participants, there were greater 
reductions in depression for non-carriers 
compared with carriers and decliners at 1mth 
follow-up. 
 
Wiggins, Whyte, 
Huggins et al., 
1992, Canada# 
Design: Prospective 
Method: Questionnaires 
at baseline (at initial 
counselling, pre-
decision), 6mth and 
12mth follow-up. 
n = 95 testers (37 increased 
risk, 58 decreased risk), 40 'no 
change' (23 decliners, 17 
uninformative result) 
Unaffected men and women at 
risk of HD participating in 
national genetic testing 
program 
Psychological distress 
(GSI:SCL-90) 
Depression (BDI) 
Well-being (GWBS) 
Difference 
scores 
used to 
minimise 
effect of 
baseline 
differences 
on 
outcomes 
At 6mths, increase in well-being for the 
decreased risk group significantly different to 
reductions in well-being in 'no change' group. 
At 12mths, improvements in psychological 
distress in tested groups differed significantly 
from deterioration in 'no change' group. 
Reductions in well-being relative to baseline in 
'no change' group at 6 and 12mths. At 12mths, 
depression had increased, compared to 
baseline, for 'no change' group compared to 
both tested groups. 
  
Adequate 
quality 
        
    
Lawson, Wiggins, 
Green et al., 
1996, Canada# 
Design: Retrospective  
Method: Utilise data 
from Wiggins et al., 
1992 study as well as 
questionnaire completed 
by clinicians and 
counsellors 
n = 95 testers (37 increased 
risk, 58 decreased risk), 23 
decliners, 17 uninformative 
result 
Men and women at risk of HD 
participating in national genetic 
testing program 
Adverse event since 
baseline -whether clinical 
and/or quantitative criteria 
were met. Clinical = 
suicide attempt/plan, 
psychiatric hospitalisation, 
depression > 2mths, 
increase in substance 
use, breakdown of 
important relationships. 
Quantitative = clinically 
relevant changes in GSI 
and BDI 
N/A No significant difference between groups in 
number of adverse events. 
Baseline depression not 
controlled for. 
They did not use self-report 
of adverse events. 
Chi-square conducted 
where there were <5 cases 
in two cells. 
* and # indicate studies with overlapping/same samples 
^ indicates studies which may have some overlap in samples 
FBOC, Familial Breast/Ovarian Cancer; GSI:SCL-90, Global Severity Index of Symptom Checklist-90; IES, Impact of Event Scale; PSS, Perceived Stress Scale; STAI, Spielberger State Trait Anxiety 
Inventory; CES-D, Center for Epidemiological Studies Depression scale; BDI, Beck Depression Inventory; HD, Huntington’s Disease; GWBS, General Well-Being Scale  
 
Table 2c. Outcomes for individuals who are ineligible for testing 
   Authors, year, 
country 
Design and Method Sample 
+ve = carrier 
-ve = non-carrier 
Measures 
(-) indicates unvalidated 
measures 
Control 
variables 
Relevant Findings Limitations 
High quality             
Geirdal & Dahl, 
2008b, Norway* 
Design: Cross-sectional 
Method: Self-report 
questionnaires; 3mths 
post-counselling for 
ineligible for testing, 6wks 
post-result for carriers 
n = 68 carriers, 174 
ineligible for testing,  
Unaffected women at risk of 
FBOC who attended a 
hereditary cancer registry.  
Anxiety and depression 
(HADS) 
Education Compared with the carriers, anxiety was 
higher in women who were ineligible for 
testing, but prevalence of disorder in both 
groups was 24%. 
Cross-sectional design 
precludes controlling for 
pre-existing differences 
between groups. 
Did not control for 
differences between groups 
in familial cancer-related 
events. 
Geirdal, Maehle, 
Heimdal et al., 
2006, Norway* 
Design: Cross-sectional 
Method: Self-report 
questionnaires 3mths 
post-counselling 
n = 239 ineligible for 
testing, 1195 age-matched 
population controls.  
Women from families with 
no identified mutation who 
are at risk of FBOC (n = 
176) or HNPCC (n = 63); 
members of a hereditary 
cancer registry. Risk groups 
combined due to lack of 
clinically significant 
differences. 
Mental QoL (MCS: SF-12) 
Cancer-related distress - 
intrusion and avoidance 
related to 'cancer risk' 
(IES) 
Age No difference between women who were 
ineligible for testing and controls in prevalence 
of mental quality of life cases. 
 
Geirdal, Reichelt, 
Dahl et al., 2005, 
Norway* 
Design: Cross-sectional 
Method: Self-report 
questionnaires 3mths 
post-counselling for 
ineligibles and 6wks post 
result for carriers 
n = 68 carriers, 239 
ineligible for testing, 10, 
000 age-matched 
population controls.  
Unaffected women at risk of 
FBOC (n = 176) or HNPCC 
(n = 63) who attended a 
hereditary cancer registry. 
Risk groups combined due 
to lack of clinically 
significant differences. 
Anxiety and depression 
(HADS) 
Psychosocial distress 
(GHQ-28) 
Hopelessness (BHS) 
Cancer-related distress - 
intrusion and avoidance 
related to 'cancer risk' 
(IES) 
Children, 
relatives 
with 
cancer, 
affected 
parent, 
marital 
status, 
education 
No difference between carriers and ineligible 
for testing in cancer-related distress. Women 
ineligible for testing reported higher anxiety, 
more anxiety cases, and lower depression 
than controls.  
FBOC women ineligible for testing reported 
higher anxiety, depression and psychosocial 
distress, and more depression and 
psychosocial distress cases than carriers. 
Cross-sectional design 
precludes controlling for 
pre-existing differences 
between groups. 
Did not control for 
differences between groups 
in familial cancer-related 
events. 
Meiser, Butow, 
Friedlander et al., 
2002, Australia  
Design: Prospective 
Method: Questionnaires 
at baseline (pre-
counselling for tested 
women), 7-10days post-
notification (post-baseline 
for untested), 4mths & 
12mths post-baseline  
n = 90 testers (30+ve, 60-
ve), 53 ineligible for testing 
controls 
Unaffected FBOC women 
who had approached a 
familial cancer clinic or 
outreach clinic 
Cancer-related distress - 
intrusion and avoidance 
related to 'being at risk of 
developing breast cancer' 
(IES) 
Anxiety (STAI) 
Depression (BDI) 
N/A Carriers had higher cancer-related distress 7–
10 days and 12mths post-notification 
compared to baseline and ineligible for testing, 
and a trend for higher cancer-related distress 
4mths post-notification (p=0.054). Compared 
with ineligible for testing, carriers reported 
reductions in anxiety at 12mths and non-
carriers reported reductions in anxiety at 7–10 
days. Trend for lower state anxiety in non-
carriers compared with ineligible for testing 
4mths post-notification.  
Did not control for 
differences between groups 
in familial cancer-related 
events 
* indicates studies with overlapping samples 
FBOC, Familial Breast/Ovarian Cancer; HADS, Hospital Anxiety and Depression Scale; HNPCC, Hereditary Non-Polyposis Colorectal Cancer; QoL, Quality of Life; MCS: SF-12, Mental Component Scale 
of the Short-Form 12 Health Survey; IES, Impact of Event Scale; GHQ-28, The General Health Questionnaire; BHS, Beck Hopelessness Scale; STAI, Spielberger State Trait Anxiety Inventory; BDI, Beck 
Depression Inventory 
 
Table 3. Vulnerability factors for individuals who decline, delay or remain ineligible for testing 
  Authors, year, 
country 
Design and Method Sample 
+ve = carrier 
-ve = non-carrier 
Measures 
(-) indicates unvalidated 
measures 
Control 
variables 
Relevant Findings Limitations 
High quality             
Geirdal & Dahl, 
2008a, Norway* 
Design: Cross-sectional 
Method: Self-report 
questionnaires 3mths 
post-counselling 
n = 238 ineligible for testing  
Unaffected women from 
families with no identified 
mutation at risk of FBOC (n = 
175) or HNPCC (n = 63); 
attendees of a hereditary 
cancer registry. Risk groups 
combined due to lack of 
clinically significant 
differences. 
Personality traits (TCI) 
Optimism (LOT) 
Hopelessness (BHS) 
Mental distress (HADS) 
Cancer-related distress - 
intrusive thoughts related 
to 'the risk of developing 
breast cancer' (IES) 
N/A HADS - number of affected female 
relatives, harm avoidant and persistent 
temperamental traits, less self-directedness 
and less optimism associated with higher 
mental distress; harm avoidance strongest 
association.  
IES - cancer in a parent, harm avoidance, 
persistence and less optimism associated 
with cancer-related distress, optimism had 
strongest association. 
 
Geirdal & Dahl, 
2008b, Norway* 
Design: Cross-sectional 
Method: Self-report 
questionnaires; 3mths 
post-counselling for 
ineligible for testing, 
6wks post-result for 
carriers 
n = 174 ineligible for testing, 
68 carriers 
Unaffected women at risk of 
FBOC who attended a 
hereditary cancer registry.  
Coping strategies (COPE) 
Anxiety (HADS) 
Education ‘Focus on and venting of emotions’, 
‘restraint coping’ and ‘behavioral 
disengagement’ associated with increased 
prevalence of anxiety disorder in women 
who were ineligible for testing. 
 
Geirdal, Maehle, 
Heimdal et al., 
2006, Norway* 
Design: Cross-sectional 
Method: Self-report 
questionnaires 3mths 
post-counselling 
n = 239 ineligible for testing, 
1195 age-matched population 
controls 
Unaffected women from 
families with no identified 
mutation who are at risk of 
FBOC (n = 176) or HNPCC (n 
= 63); attendees of a 
hereditary cancer registry. 
Risk groups combined due to 
lack of clinically significant 
differences. 
Risk group: 
Mental QoL (MCS: SF-12) 
Cancer-related distress - 
intrusion and avoidance 
related to 'cancer risk' 
(IES) 
Controls:  
Quality of life (SF-36) 
 Risk of poor mental QoL associated with 
being unpartnered for controls and women 
ineligible for testing. 
Poor mental QoL was associated with 
intrusion and avoidance in both groups. 
 
Lerman, Hughes, 
Lemon et al., 
1998, USA 
Design: Prospective 
cohort study 
Method: Baseline (pre-
education) phone 
interview, 1mth & 6mth 
follow-up phone 
interviews 
n = 206 testers (97+ve, 109-
ve), 121 decliners 
FBOC men and women from 
mutation-positive families 
registered at a hereditary 
cancer unit 
Low-moderate stress vs 
high stress; 0-10 vs 11-
33, respectively scored 
for intrusive thoughts 
about 'having cancer in 
the family' (IES) 
Depression (CES-D) 
Baseline 
depression, 
gender, 
affected 
status, 
marital status 
For high stress, decliners 8x more likely to 
become depressed compared with non-
carriers at 1mth follow-up.  
For unaffected high stress, higher rates of 
depression in decliners (44%) compared 
with carriers (24%) and non-carriers (16%) 
at 6mth follow-up. 
% affected not reported 
* indicates studies with overlapping samples 
FBOC, Familial Breast/Ovarian Cancer; HNPCC, Hereditary Non-Polyposis Colorectal Cancer; TCI, The Temperament and Character Inventory; LOT, Life Orientation Test; BHS, Beck Hopelessness 
Scale; HADS, Hospital Anxiety and Depression Scale; IES, Impact of Event Scale; COPE, Coping Orientation to Problems Experienced Scale; QoL, Quality of Life; MCS: SF-12, Mental Component Scale 
of the Short-Form 12 Health Survey; SF-36, Short-Form 36 Health Survey; CES-D, Center for Epidemiological Studies Depression scale 
 
 
 
Appendix 1. Disease characteristics       
Disease Risk for mutation carriers Prevention options Screening options Treatment options 
Familial 
Breast/Ovarian 
Cancer (FBOC) 
Up to 85% breast cancer risk 
and 60% ovarian cancer risk 
by age 70 
Chemoprevention 
Prophylactic surgery - 
removal of breasts and/or 
ovaries 
Mammogram 
Breast ultrasound 
MRI 
Transvaginal ultrasound 
(TVU) 
CA-125 blood test for ovarian 
cancer 
Surgery 
Chemotherapy 
Radiation therapy 
Hormone therapy 
Targeted therapies 
Hereditary Non-
Polyposis Colorectal 
Cancer (HNPCC) 
80-85% 
Increased risk also for cancer 
of the uterus, stomach, small 
intestine, pancreas, kidney, 
ureter and ovary 
Prophylactic surgery - 
removal of part or all of colon 
Fecal occult blood test 
Colonoscopy 
Urine cytology 
TVU 
CA-125 
Surgery 
Chemotherapy 
Radiation 
Li-Fraumeni 
Syndrome (LFS) - 
high risk of various 
cancers from early 
childhood 
Up to 90% lifetime risk, 20% 
risk before age 20 
None (possible prophylactic 
mastectomy for female 
mutation carriers) 
Unclear due to risk of cancer 
at multiple sites and possible 
increased sensitivity to 
radiation, but regular medical 
checks are carried out 
Available but vary depending 
on type of cancer 
Familial Melanoma 
(FM) 
60-90% 
Possibility of concomitant 
increased pancreatic cancer 
risk (<20%) 
Limitation of sun exposure Skin examination Surgery 
Chemotherapy 
Immunotherapy 
Radiation 
Huntington’s 
Disease (HD) - 
progressive 
neuropsychiatric 
disorder 
100% - late onset None Physical and psychological 
screening to identify signs of 
disease onset 
None, although treatments 
are available to manage and 
lessen symptoms 
 
